J Biol Regul Homeost Agents. 2018 Sep-Oct;32(5):923-929.
Treatment mechanism of tolerogenic dendritic cells on rheumatoid arthritis.
- 1 Department of Rheumatology and Immunology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- 2 Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong, China.
This study aims to explore the possible mechanism of treatment of collagen-induced rheumatoid arthritis (RA) by tolerogenic dendritic cells (tDCs). Different methods were used to induce and cultivate tDCs, and suitable conditions for tDC cultivation were explored. The experimental RA induced by collagen in mouse was treated by the obtained tDCs, and the possible mechanism was explored. The serum concentration of TNF-α, IFN-β, IL-4 and anti-type II collagen antibody were detected by ELISA. The anti-type II collagen antibody of mice without treatment was higher than that without disease onset, while the Blank-DC group, VIP-DC group and Bay-D had no statistically significant differences (P>0.05). Compared to the group without disease onset, the TNF-α level of those without treatment was significantly higher, while INF-γ, IL-1β and IL-4 concentration showed no significant difference (P>0.05). Compared to the untreated group, the TNF-α and IL-1β concentration after VIP-DC treatment were significantly decreased, while IL-4 was increased (P less than 0.05). In summary, VIP-DC and Bay-DC alleviate joint inflammation, synovitis and bone erosion by reducing the production of anti-type II collagen antibody, inhibiting proinflammatory factors and increasing inflammation inhibitors.